MarginsXMarginsX
Home › Markets › Health Care › CTNM

Contineum Therapeutics Inc. (CTNM)

CTNM trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$9.67
-1.93% on the day
Market cap
$379.7M
Small cap
Revenue · 2024
$0
-100.0% on 2023
Net income · 2024
-$42.3M

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2024-12-31, https://www.sec.gov/Archives/edgar/data/1855175/000143774925006458/0001437749-25-006458-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2024-12-31.

Profile

FieldValue
TickerCTNM on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO year2024
SEC CIK0001855175
SEC industry codePharmaceutical Preparations
Incorporated inDE

Financials · 2024

LineValue
Revenue$0
Net income-$42.3M
Operating income-$50.9M
Net marginNeeds revenue and net income
Operating marginOperating income not reported
Revenue growth-100.0%
Cash$21.9M
Total assets$212.8M
P/E (computed)Net income was not positive
P/S (computed)Needs market cap and revenue

Warning signs

Cash runway
17.4 months
$75.2M cash at September 30, 2026
Share count, 1 year
No year-earlier count
Going-concern doubt
No
10-Q filed November 3, 2026
Insider net buying, 12 months
-$1.9M
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-11-03
Cash and burn$75.2M cash; operating cash flow -$13.0M a quarter.Report 2026-09-30
Shares outstanding39,265,813 (2026-10-30).Cover page 2026-10-30
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 3 424B5 takedowns, 1 at the marketLatest 2026-03-05
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorErnst & Young LLP, San Diego, California, United StatesPCAOB Form AP 2026-03-13
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $1.9M on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
Not filed-$18.7M-$11.1M$75.2MNo debt tagsNeeds four quarters10-Q 2026-11-03
Q2 2026
2026-06-30
Not filed-$15.2M-$11.5M$14.7MNo debt tagsNeeds four quarters10-Q 2026-11-03
Q1 2026
2026-03-31
Not filed-$14.5M-$16.3M$20.2MNo debt tagsNeeds four quarters10-Q 2026-11-03
Q4 2025
2025-12-31
Not filed-$15.2M-$13.0M$75.6MNo debt tagsNeeds four quarters10-K 2026-03-05
Q3 2025
2025-09-30
Not filed-$12.8M-$12.2M$42.6MNo debt tagsNeeds four quarters10-Q 2026-11-03
Q2 2025
2025-06-30
Not filed-$16.0M-$15.7M$20.8MNo debt tagsNeeds four quarters10-Q 2026-11-03
Q1 2025
2025-03-31
Not filed-$16.0M-$14.4M$22.5MNo debt tagsNeeds four quarters10-Q 2026-11-03
Q4 2024
2024-12-31
$0-$14.6M-$10.2M$21.9MNo debt tags$010-K 2025-03-06

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B52026-03-05
Latest annual report10-K2026-03-05
Latest quarterly / interim10-Q2026-11-03
Latest current report8-K2026-11-03
Latest proxyDEFA14A2026-04-30

Source: SEC EDGAR submissions feed, 204 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week+3.6%
1 month+17.1%
3 months-35.6%
Year to date-13.7%
1 year-9.5%
From 52-week high-43.9%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
PBYIPuma Biotechnology Inc$7.34-5.53%$379.5M
CRMDCorMedix Inc.$4.82+3.43%$383.4M
RLMDRelmada Therapeutics Inc.$3.61-14.25%$385.2M
IRDOpus Genetics Inc.$4.04+1.51%$390.5M
PEPGPepGen Inc.$4.19-3.90%$395.0M
SPRYARS Pharmaceuticals Inc.$3.59-7.71%$360.9M
ASPEAspen Neuroscience Inc.$12.23-2.86%$355.6M
PRTAProthena Corporation plc$7.97-2.33%$409.3M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier